Back to 
Glenmede Trust Co. N.A.
Glenmede Trust Co. N.A.
NTLA
17 quarters
Position history for Glenmede Trust Co. N.A.'s holdings in Intellia Therapeutics, Inc.
No. Glenmede Trust exited its NTLA (Intellia Therapeutics) position in Q4 2022. Its Q3 2022 13F listed 4,406 shares worth $246,000. Glenmede Trust first reported NTLA in Q4 2018 and held it in 15 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
-$37,000
Total Shares Change
-2,750
Quarter-by-Quarter History
Other major holders of NTLA: ARK Investment Management LLC